Future directions etoposide therapy Etoposide important chemotherapeutic agent treatment patients germ cell tumors lymphomas small cell lung cancer SCLC optimal use clear schedule dependency critical importance preliminary studies prolonged schedule etoposide administration days effective standard schedule Results several Phase II studies chronic oral etoposide administration induces occasional responses resistant tumors higher-than-expected response rates patients germ cell tumors SCLC Preliminary show etoposide absorption low-dose schedule days observations etoposide new drug chronic schedule Further exploration schedule dependency etoposide Etoposide useful patients gastric ovarian carcinoma unknown primary site Several drugs synergistic additive combination chemotherapy possibility topoisomerase inhibitors etoposide activity drug resistance realm human testing 